Emma Groarke, Hematologist at the National Institutes of Health (NIH), shared a post on X/Twitter:
“Nice paper from France in British Journal of Haematology on a series of relapsed/refractory T- Large granular lymphocytic leukemia (LGL) patients treated with Ruxolitinib.
Some response observed in 86% though complete response in 14%.
A potentially good option for patients going forward.”
Additional information.